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To the Editor:
Masseli et al1 report the use of
antegrade stent grafting to treat acute
complications early after surgery for
acute type A aortic dissection. The
previously surgically sewn ascend-
ing or arch Dacron graft was used
as the entry point to antegrade de-
ploy a stent graft in 5 patients with
contained rupture or malperfusion.
In 1 patient, the stent graft was in-
serted to treat exsanguination at the
distal total arch suture line at the
end of the primary operation. In
the remaining 4 patients, the treat-
ment occurred a few days after the
primary procedure.
More important, in their article,
reopening of a fresh sternotomy to
access the aorta in an unstable patient
may be more expeditious than strug-
gling through femoral access andwires
manipulations in a dissected and mal-
perfused descending and abdominal
aorta. We congratulate the authors for
getting out of trouble by thinking
outside the usual ‘‘stent-graft box.’’
The availability of stent grafts gives
all of us additional tools to deal with
difficult problems that traditional
methods may have been unable to
control as well. More important,
all cardiovascular surgeons should
become sufficiently familiar with all
potential options at their disposal.
However, we find it often difficult to
justify the reluctance to perform some
form of frozen elephant trunk (FET) to244 The Journal of Thoracic and Cprevent most of the complications
successfully treated herein. Growing
experience with FET techniques
has shown benefits in simplifying
complex 2-stage aortic operations,
stabilizing distal aortic lesions, avoid-
ing reliance on a fragile aortic
anastomosis, and potentially correct-
ing distal malperfusion.2 Exclusion
of the descending thoracic aorta with
appropriate length stent grafting can
decrease long-term aortic dilatation
and rupture risk.3 In addition, the
FET, when combined with a total
arch replacement, can make the possi-
bility of type I proximal endoleak and
proximal migration nonexistent.
We would encourage a more
elective use of antegrade stent grafting
to avoid having to resort to the
emergent bailouts described herein
or, worse yet, risk losing patients
from rupture or malperfusion after
discharge from our units.
Eduard Quintana, MD
Murat Ugur, MD
Alberto Pochettino, MD
Division of Cardiovascular Surgery
Mayo Clinic
Rochester, Minn
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In our original article, we described
antegrade stent placement as a useful
bailout strategy for complications aris-
ing after surgical treatment of acuteardiovascular Surgery c July 2013type A dissections.1 In their letter
to the editor, Quintana et al propose
the frozen elephant trunk technique
(FET) as the initial procedure to avoid
complications and the need for bailout
strategies, suchas theonewepresented,
and argue that the benefits of the FET
have been shown. The cited reference
reports about a product-associated reg-
istry and the analysis of a subset of 68
procedures that have been performed
in patients with acute type A aortic
dissections.2 A newer publication con-
cerning this registry, the International
E-vita open Registry,3 is reporting
about 274 treated patients, containing
88 patientswith acute typeA aortic dis-
section. Themortality in this groupwas
18%, and the overall rate of spinal cord
injuries was 8%. In our opinion, these
reports with relatively small numbers
give no evidence for benefits of the
FET in relation to conventional tech-
niques that we extended with the
method we presented.
Nevertheless, in total arch replace-
ment, the FET gives some theoretical
advantages that could outweigh its
possible disadvantages, such as longer
circulatory arrest times, higher inci-
dences of spinal cord ischemia, or
device-related problems. The FET
has to be further evaluated to answer
these questions. Additional products
and ongoing growing experience will
help to find the right position for the
FET, which was, until now, mainly
bound to a single product.
Franz Joseph Masseli, MD
Wolfgang Schiller, MD
Clinic for Cardiac Surgery
University Hospital Bonn
Bonn, Germany
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MANAGEMENT OF LUNG
CANCER IN THE UNITED
KINGDOM BETWEEN 2004 AND
2009
To the Editor:
We would like to comment on sur-
gical management of the lung in the
United Kingdom for the period from
2004 to 2009. Surgical management
offers can be curative but there are
little data on the subsequent prognosis
of patients in the United Kingdom.
Pneumonectomy and lobectomy have
reported mortality rates of 6% to
8% and 2% to 4%, respectively.1-4
Our study aimed to assess diagnostic
methods, staging, and long-term prog-
nosis in surgically managed patients
with lung cancer. We retrospectively
analyzed the medical notes of all
surgically managed lung cancer
patients in a National Health Service
hospital between 2004 and 2009. Only
40 patients were identified, 80% had
non–small-cell lung cancer and in the
remaining patients no tissue diagnosis
was made. Ninety percent were staged
node negative via a combination of
both positron emission tomography
and computerized tomography scan-
ning. No patients received preoperative
down-staging adjuvants.
Mortality rates at both 6 months and
1 year was 25%. There were no surgi-
cal deaths or deaths in the immediateThe Journalpostoperative period. All patients
who died within 6 months of surgery
had radiologic evidence of metastatic
disease and lung cancer specified on
theirmedical cause of death certificate.
Thirty percent of patients received
postoperative chemotherapy, 3% of
patients received postoperative radio-
therapy, and 6% of patients received
both chemotherapy and radiotherapy.
In the patients who died, the median
survival time was 5.3 months. Three
of the 10 patients who died had evi-
dence of metastatic thoracic disease
at surgery. Tumor staging was compa-
rable between those who died and
those who were cured.
In conclusion, surgicalmanagement
was curative (defined as no evidence of
metastatic disease at 1 year postopera-
tively) in 30 patients (75%). In those
patientswhowere not cured, prognosis
was poor and comparable with those
who did not have surgery. Tumor
staging did not affect outcome.
Our study was largely historical and
showed practice before the update to
the guidelines in 20115 such that
now patients undergoing surgery
with curative intent should first have
hilar and mediastinal lymph node
sampling, or otherwise undergo bloc
resection. Second, many of our pa-
tients proceeded to surgery without
histologic evidence of disease. Ob-
taining histologic proof can be diffi-
cult; tumors on the periphery of the
lung cannot be visualized with con-
ventional bronchoscopy but the new
guidelines have evolved to include en-
dobronchial ultrasound (EBUS),
which may reduce the number of tho-
racotomies occurring without priorof Thoracic and Cardiovascular Surgehistologic diagnosis. The limitations
to our study stem from our limited
number of cases, poorly maintained
registry, and its historical nature. How-
ever, we hope this letter encourages
others to perform a larger study that
examines the effects of EBUS and pre-
operative staging on results. This is
very important because the costs in-
volved in creating an EBUS service
are significant and must be justified
in the context we have outlined.
Jessica Gubbin, BAa
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